Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazel, Danielle, Zhang, Shannon, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113513/
https://www.ncbi.nlm.nih.gov/pubmed/35592355
http://dx.doi.org/10.2147/LCTT.S360574
Descripción
Sumario:Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in early trials. Here we focus on tepotinib and capmatinib in regards to molecular characteristics, early preclinical and clinical data, and the emerging role in future studies and clinical practice.

Ejemplares similares